TPGS2

Across TCGA pan-cancer cohorts, TPGS2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TPGS2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TPGS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TPGS2 expression acts as an unfavorable survival marker.

GBM and PDAC are the cancer types where TPGS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.628	1.000	.006	13	view →
PDAC	OS	Quartile	III,IV	0.419	0.984	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TPGS2–GBM (DFS)

Open the GBM breakdown →